Lumacaftor-rescued F508del-CFTR has a modified bicarbonate permeability

Deletion of phenylalanine at position 508, F508de1, the most frequent mutation among Cystic fibrosis (CF) patients, destabilizes the protein, thus causing both a folding and a trafficking defect, resulting in a dramatic reduction in expression of CFTR. In vitro treatment with lumacaftor produces an enhancement of anion transport in cells. We studied the permeability properties of the CFTR mutant F508de1 treated with the corrector lumacaftor, showing that the rescued protein has selectivity properties different than the wild type CFTR, showing an augmented bicarbonate permeability. This difference would indicate a diverse conformation of the rescued F508del-CFIR, that is plausibly reflected on an improper regulation of the airway surface liquid. lessening the efficacy of the corrector. Our findings rather support the idea that a combination of correctors would be required to address the MR-dependent bicarbonate permeability. (C) 2019 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.